Showing 1 to 12 of 21 results
CVS Faces Class-Action Lawsuit Over Obesity Drug Coverage
A class-action lawsuit targets CVS Caremark for removing coverage of Eli Lilly's Zepbound, replacing it with Novo Nordisk's Wegovy, despite medical professionals arguing the drugs aren't interchangeable, impacting an estimated 25-30 million people.
CVS Faces Class-Action Lawsuit Over Obesity Drug Coverage
A class-action lawsuit targets CVS Caremark for removing coverage of Eli Lilly's Zepbound, replacing it with Novo Nordisk's Wegovy, despite medical professionals arguing the drugs aren't interchangeable, impacting an estimated 25-30 million people.
Progress
24% Bias Score
High Costs, Inconsistent Coverage Limit Access to Popular Obesity Drugs
High prices and inconsistent insurance coverage limit access to the popular obesity medications Wegovy and Ozempic, despite falling costs and some employer-sponsored plans expanding coverage; the medications cost around $500 per month without insurance, forcing doctors to find creative solutions and...
High Costs, Inconsistent Coverage Limit Access to Popular Obesity Drugs
High prices and inconsistent insurance coverage limit access to the popular obesity medications Wegovy and Ozempic, despite falling costs and some employer-sponsored plans expanding coverage; the medications cost around $500 per month without insurance, forcing doctors to find creative solutions and...
Progress
40% Bias Score
GLP-1 Agonists Show Potential for Reducing Obesity-Related Cancer Risk
A new study of 170,030 obese and diabetic adults in the US found that GLP-1 receptor agonists (Ozempic, Wegovy, etc.) may modestly reduce the risk of 14 obesity-related cancers and all-cause mortality, especially in women, compared to DDP-4 inhibitors.
GLP-1 Agonists Show Potential for Reducing Obesity-Related Cancer Risk
A new study of 170,030 obese and diabetic adults in the US found that GLP-1 receptor agonists (Ozempic, Wegovy, etc.) may modestly reduce the risk of 14 obesity-related cancers and all-cause mortality, especially in women, compared to DDP-4 inhibitors.
Progress
44% Bias Score
Novo Nordisk's Telemedicine Deal to Counter Eli Lilly in Obesity Drug Market
Novo Nordisk partnered with Hims & Hers Health to sell its Wegovy weight-loss drug through telemedicine platforms at discounted prices, directly competing with Eli Lilly's Zepbound strategy amid insurance coverage challenges and following a recent stock decline of over 30% since January 2025, after ...
Novo Nordisk's Telemedicine Deal to Counter Eli Lilly in Obesity Drug Market
Novo Nordisk partnered with Hims & Hers Health to sell its Wegovy weight-loss drug through telemedicine platforms at discounted prices, directly competing with Eli Lilly's Zepbound strategy amid insurance coverage challenges and following a recent stock decline of over 30% since January 2025, after ...
Progress
40% Bias Score
High Cost of GLP-1 Weight Loss Drugs Limits Cost-Effectiveness
A JAMA Health Forum study found that despite improved health outcomes, GLP-1 weight loss medications like Wegovy and Zepbound are not currently cost-effective due to high net prices, patient non-persistence, and insurer churn; price reductions of 30% for tirzepatide and 82% for semaglutide are neede...
High Cost of GLP-1 Weight Loss Drugs Limits Cost-Effectiveness
A JAMA Health Forum study found that despite improved health outcomes, GLP-1 weight loss medications like Wegovy and Zepbound are not currently cost-effective due to high net prices, patient non-persistence, and insurer churn; price reductions of 30% for tirzepatide and 82% for semaglutide are neede...
Progress
56% Bias Score
Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments
Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.
Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments
Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.
Progress
36% Bias Score
Weight Regain Follows GLP-1 Medication Discontinuation
A study in BMC Medicine reveals that patients stopping GLP-1 weight-loss drugs like Wegovy and Ozempic regain weight within two months, highlighting the chronic nature of obesity and need for ongoing management, despite continued healthy habits.
Weight Regain Follows GLP-1 Medication Discontinuation
A study in BMC Medicine reveals that patients stopping GLP-1 weight-loss drugs like Wegovy and Ozempic regain weight within two months, highlighting the chronic nature of obesity and need for ongoing management, despite continued healthy habits.
Progress
36% Bias Score
US GLP-1 Drug Affordability Crisis
High costs and limited insurance coverage of GLP-1 weight-loss drugs like Ozempic and Wegovy are creating an affordability crisis in the US, with millions losing coverage in 2025; potential solutions include allowing compounding pharmacies to produce personalized prescriptions and revoking patent ex...
US GLP-1 Drug Affordability Crisis
High costs and limited insurance coverage of GLP-1 weight-loss drugs like Ozempic and Wegovy are creating an affordability crisis in the US, with millions losing coverage in 2025; potential solutions include allowing compounding pharmacies to produce personalized prescriptions and revoking patent ex...
Progress
52% Bias Score
Novo Nordisk CEO Steps Down Amidst Market Challenges and Competition
Novo Nordisk CEO Lars Fruergaard Jorgensen resigned Friday due to market challenges and declining share prices after Eli Lilly's Zepbound surpassed Wegovy in US prescriptions since mid-March; former CEO Lars Rebien Sorensen will join the board as an observer.
Novo Nordisk CEO Steps Down Amidst Market Challenges and Competition
Novo Nordisk CEO Lars Fruergaard Jorgensen resigned Friday due to market challenges and declining share prices after Eli Lilly's Zepbound surpassed Wegovy in US prescriptions since mid-March; former CEO Lars Rebien Sorensen will join the board as an observer.
Progress
40% Bias Score
Decreased Insurance Coverage for GLP-1 Agonists Amidst Soaring Demand
Between 2024 and 2025, insurance coverage for Ozempic dropped 22%, affecting 1.1 million people, while Zepbound saw a 14% increase in uninsured individuals (4.9 million), despite a 300% rise in Zepbound fills and doubled Ozempic fills since early 2024, highlighting the rising cost of these medicatio...
Decreased Insurance Coverage for GLP-1 Agonists Amidst Soaring Demand
Between 2024 and 2025, insurance coverage for Ozempic dropped 22%, affecting 1.1 million people, while Zepbound saw a 14% increase in uninsured individuals (4.9 million), despite a 300% rise in Zepbound fills and doubled Ozempic fills since early 2024, highlighting the rising cost of these medicatio...
Progress
36% Bias Score
Eli Lilly Q4 Earnings Beat Expectations, Sending Shares Higher
Eli Lilly's Q4 2024 revenue reached \$13.53 billion, a 45% year-over-year increase, exceeding adjusted EPS expectations; however, Mounjaro and Zepbound sales slightly missed forecasts, yet still contributed \$5.44 billion in revenue, boosting the stock to its highest level since October.
Eli Lilly Q4 Earnings Beat Expectations, Sending Shares Higher
Eli Lilly's Q4 2024 revenue reached \$13.53 billion, a 45% year-over-year increase, exceeding adjusted EPS expectations; however, Mounjaro and Zepbound sales slightly missed forecasts, yet still contributed \$5.44 billion in revenue, boosting the stock to its highest level since October.
Progress
48% Bias Score
GLP-1 Drug Adherence: Cost, Side Effects, and Income Disparities
A JAMA Network Open study reveals that 65% of patients without diabetes stopped using GLP-1 weight loss drugs within a year, compared to 46% of those with Type 2 diabetes; side effects and cost were the main reasons, while higher income and weight loss correlated with continued use; Noom's layoffs e...
GLP-1 Drug Adherence: Cost, Side Effects, and Income Disparities
A JAMA Network Open study reveals that 65% of patients without diabetes stopped using GLP-1 weight loss drugs within a year, compared to 46% of those with Type 2 diabetes; side effects and cost were the main reasons, while higher income and weight loss correlated with continued use; Noom's layoffs e...
Progress
40% Bias Score
Showing 1 to 12 of 21 results